Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-01

Study Completion Date

2020-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Large population studies of hypopituitary adults (patients with pituitary gland failure) on conventional hormone replacement, but not growth hormone, have an approximate two fold increase in death rate (mortality). The vast majority of this excess mortality relates to vascular disease. While it is possible that overreplacement with steroids, underreplacement with thyroid hormones and sex hormone deficiency contribute, there are increasing data to support a role for GH in the cause of the excess vascular risk. Although a number of surrogates of vascular risk are described in patients with GH deficiency (GHD), how these translate mechanistically into atherothrombotic (blockage of the arteries) disease has not been fully elucidated.

This proposed study will analyse both traditional (body composition, serum lipids, handling of sugars)and more complex markers (inflammation, procoagulation, fibrinolysis) of vascular risk/disease. In addition the study will examine 24hr blood pressure, arterial wall thickness, clot structure and function, as well as platelet action. Measurements will be performed at baseline and will be reassessed after patients have been on a stable dose of GH replacement for at least three months.

The results of the study will characterise risk factors for vascular disease, and take this a step further to elucidate how these changes translate mechanistically in to vascular damage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

NCT01562834

Growth Hormone Disorder Adult Growth Hormone Deficiency

COMPLETED PHASE4

Effect of 5 Years of GH Replacement on Atherosclerosis

NCT00462475

Hypopituitarism Pituitary Tumors Growth Hormone Deficiency

COMPLETED

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

NCT02782208

Hypopituitarism Insulin Resistance Endocrine System Diseases +4 more

COMPLETED NA

Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

NCT01734447

Foetal Growth Problem Small for Gestational Age

COMPLETED PHASE4

A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury

NCT00638053

Brain Injuries Growth Hormone Deficiency Dwarfism

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypopituitary Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Growth Hormone Therapy

Intervention Type DRUG

Control Group

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Growth Hormone Therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to give written consent
* Adults with confirmed GHD (Insulin stimulation test \<3ug/L)
* Other hormone replacement therapy stable for at least three months

Exclusion Criteria

* active malignancy
* an acute vascular event within three months of the study
* any therapy other than hormone replacement
* serum creatinine \>120 micromol/l
* abnormal LFTs (ALT\>3 fold upper limit of normal)

Minimum Eligible Age

16 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No